MEMPHIS, TN (December 5, 2017) — PMC Biogenix Inc. announces that effective January 1, 2018 or as contracts permit, prices for products sold under the trademarks Armoslip®, Hystrene®, Industrene®, Kemamide®, Kemester®, and Lubrazinc® will increase by 3% (three percent). Customers with questions should contact their sales manager or their local customer service contact.   About

MOUNT LAUREL, NJ (December 4, 2017) — PMC Group France, a wholly owned subsidiary of PMC Group International Inc., which is an independent arm of PMC Group Inc., announced the acquisition of the pharma business of Isochem SAS of France. This is a fully integrated business comprised of research, product/process development, regulatory approvals, pilot scale

MOUNT LAUREL, NJ (October 28, 2017) — PMC YM-Pharma Private Ltd., a subsidiary of PMC Group International, an independent arm of PMC Group Inc., announced the acquisition of the assets of Yegna Manojavam Drugs and Chemicals Ltd (YMDCL) of Hyderabad, India. The cGMP manufacturing facility of YMDCL is one of the largest fluoroquinolone drug manufacturers

CARROLLTON, KY (October 01, 2017) – PMC Organometallix, Inc., a wholly owned subsidiary of PMC Group, has expanded its distribution agreement with Safic-Alcan to include Eastern Europe providing customers with sales, order fulfillment, and technical support. Effective immediately, Safic-Alcan will serve as an authorized distributor of PMC Organometallix’ s FASCAT® catalysts and Fine Chemicals—highly selective catalysts